The U.S. Food and Drug Administration (FDA) approved Mylan NV's generic version of GlaxoSmithKline-developed blockbuster asthma treatment Advair, driving shares of Mylan 7 percent higher on Wednesday.
from Reuters: Health News https://reut.rs/2SfFFd3
via IFTTT
from Reuters: Health News https://reut.rs/2SfFFd3
via IFTTT
إرسال تعليق